Alcon stock acquires Neurotech before the Xetra open today

Published on 10/21/2026 at 07:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Alcon announced a Neurotech Pharmaceuticals acquisition on October 20, 2026. At Lang & Schwarz the stock trades pre-market at EUR 60.42 on October 21, 2026.

Acquisition and business scope

Alcon announced the acquisition of Neurotech Pharmaceuticals on October 20, 2026.
Alcon operates across Surgical and Vision Care, with products reaching people in more than 140 countries.
Alcon stock trades pre-market at EUR 60.42 at 7:45 a.m. CEST at Lang & Schwarz on October 21, 2026.

Architectural photography of a modern medical technology corporate headquarters. Glass curtain wall facade with geometric steel grid, elevated skywalks connecting two wings, landscaped plaza with reflecting pool, cool blue-grey tonality — Alcon CH0432492467: Modernes Med Tech Hauptquartier mit Glasfassade, verbindenden Skywalks und einem Spiegelbecken, Illustration mit AI erstellt.

Alcon announced the acquisition of Neurotech Pharmaceuticals on October 20, 2026, according to Markets Insider. Alcon stock trades pre-market at EUR 60.42 at 7:45 a.m. CEST at Lang & Schwarz on October 21, 2026.

Neurotech deal announced

The transaction adds Neurotech Pharmaceuticals and its ENCELTO eye treatment to Alcon’s retina portfolio. The report said Alcon may make additional contingent payments tied to commercial milestones.

Alcon’s business scope

Alcon develops Surgical and Vision Care products for eye-care needs, and its products reach people in more than 140 countries, according to the company’s investor-relations site. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Alcon stock.

Market context: Market report SMI.

More news and analysis on Alcon stock